Recent advances and future therapy development for Alzheimer’s disease and related disorders  

作　　者：Megan Hong Gal Bitan 

机构地区：[1]Department of Neurology,David Geffen School of Medicine,University of California Los Angeles,Los Angeles,CA,USA [2]Department of Chemistry and Biochemistry,University of California Los Angeles,Los Angeles,CA,USA [3]Molecular Biology Institute,University of California Los Angeles,Los Angeles,CA,USA [4]Brain Research Institute,University of California,Los Angeles,CA,USA

出　　处：《Neural Regeneration Research》2024年第9期1877-1878,共2页中国神经再生研究（英文版）

基　　金：supported by NIH grants RF1NS126406 and R21NS130326;by a generous gift from the Binder Foundation (to GB)

摘　　要：Over 55 million people globally live with Alzheimer’s disease(AD)or related dementias(ADRD)and the number is expected to double every twenty years.Unt i l recent l y,onl y symptomatic treatments were available to patients with AD,including acetylcholine esterase inhibitors,of which the last one,galantamine,was approved by the US Food and Drug Administration(FDA)in 2001.

关 键 词：ALZHEIMER globally patients 

分 类 号：R749.16[医药卫生—神经病学与精神病学]